Short answer
Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on May 27, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholders approved the 2026 Omnibus Share and Incentive Plan at the May 26, 2026 annual meeting.
Arbutus Biopharma Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Shareholders approved the 2026 Omnibus Share and Incentive Plan at the May 26, 2026 annual meeting
- Plan authorizes issuance of 16,300,000 common shares for equity compensation
- Replaces the 2011 and 2016 share compensation plans
- Potential dilution and expanded employee incentive capacity are key shareholder implications
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All five director nominees elected, with support ranging from 126.7M to 139.3M votes
- 2026 Omnibus Share and Incentive Plan approved with 138.9M votes for, authorizing expanded equity compensation capacity
- Executive compensation approved on an advisory basis with 137.6M votes for
- Ernst & Young LLP reappointed auditor for fiscal 2026 with 164.4M votes for
- Matthew Gline received the lowest director support, with 126.7M votes for and 19.8M withheld
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arbutus Biopharma Corp 8-K filings
Get the next ABUS 8-K as it lands
Follow ABUS for push alerts, or ask the research agent what this filing means.